Effect of acarbose on cardiovascular events and new-onset diabetes in patients with coronary heart disease and impaired glucose tolerance

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339(4), 229–234 (1998).
  Medline CASGoogle Scholar
• 2 Xu Y, Wang L, He J et al. Prevalence and control of diabetes in Chinese adults. JAMA 310(9), 948–959 (2013). • Half of the adults in China are thought to have prediabetes, in other words, they have impaired fasting glucose and/or impaired glucose tolerance.
  Medline CASGoogle Scholar
• 3 Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J. Am. Coll. Cardiol. 59(7), 635–643 (2012).
  Medline CASGoogle Scholar
• 4 Ryden L, Grant PJ, Anker SD et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary. Diab. Vasc. Dis. Res. 11(3), 133–173 (2014).
  MedlineGoogle Scholar
• 5 Hanefeld M, Fischer S, Julius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39(12), 1577–1583 (1996).
  Medline CASGoogle Scholar
• 6 Balfour JA, McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 46(6), 1025–1054 (1993).
  Medline CASGoogle Scholar
• 7 Shimabukuro M, Higa M, Yamakawa K, Masuzaki H, Sata M. Miglitol, alpha-glycosidase inhibitor, reduces visceral fat accumulation and cardiovascular risk factors in subjects with the metabolic syndrome: a randomized comparable study. Int. J. Cardiol. 167(5), 2108–2113 (2013). • The α-glucosidase inhibitors include acarbose, miglitol and voglibose, with acarbose being the most extensively studied.
  MedlineGoogle Scholar
• 8 Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 373(9675), 1607–1614 (2009).
  Medline CASGoogle Scholar
• 9 He K, Shi JC, Mao XM. Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients. Ther. Clin. Risk Manag. 10, 505–511 (2014).
  Medline CASGoogle Scholar
• 10 Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, De Grauw WJ. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst. Rev. (4) 505–511 (2006).
  Google Scholar
• 11 Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 3639–3645(2), (2005).
  Google Scholar
• 12 Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J. Clin. Endocrinol. Metab. 91(3), 837–842 (2006).
  Medline CASGoogle Scholar
• 13 Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290(4), 486–494 (2003). •• Acarbose treatment resulted in a significant 25% reduction in newly diagnosed diabetes and suggested benefits on cardiovascular events.
  Medline CASGoogle Scholar
• 14 Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur. Heart J. 25(1), 10–16 (2004). • The efficacy of acarbose 100 mg three-times daily in preventing the development of diabetes.
  Medline CASGoogle Scholar
• 15 Holman RR, Coleman RL, Chan JCN, Chiasson JL, Feng H, Ge J, Gerstein HC, Gray R, Huo Y, Lang Z et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 5(11), 877–886 (2017). •• The cardiovascular effect of acarbose in patients with established Type 2 diabetes mellitus (T2DM), and in those with impaired glucose tolerance (IGT) but not cardiovascular disease (CVD).
  Medline CASGoogle Scholar
• 16 Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359(9323), 2072–2077 (2002).
  Medline CASGoogle Scholar
• 17 Standl E, Schnell O, McGuire DK. Heart failure considerations of antihyperglycemic medications for Type 2 diabetes. Circ. Res. 118(11), 1830–1843 (2016). • Heart failure is now becoming a serious complication in T2DM patients.
  Medline CASGoogle Scholar
• 18 Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Cardiac Failure 12(9), 694–699 (2006). • Acarbose could improve the function of left ventricle.
  Medline CASGoogle Scholar
• 19 Standl Eberhard, Theodorakis Michael J, Erbach Michael, Schnell Oliver, Tuomilehto Jaakko. On the potential of acarbose to reduce cardiovascular disease. Cardiovasc. Diabetol. 13(81), 1186–1475 (2014).
  Google Scholar
• 20 DiNicolantonio JJ, Bhutani J, O'Keefe JH. Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. Open Heart 2(1), e000327 (2015).
  MedlineGoogle Scholar
• 21 Delorme S, Chiasson JL. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus. Curr. Opin. Pharmacol. 5(2), 184–189 (2005).
  Medline CASGoogle Scholar
• 22 Schaper MHF. Acarbose: oral antidiabetes drug with additional cardiovascular benefits. Expert Rev. Cardiovasc. Ther. 6(3), 343–368 (2008).
  MedlineGoogle Scholar
• 23 Ji L, Lu J, Weng J et al. China type 2 diabetes treatment status survey of treatment pattern of oral drugs users. J. Diabetes 7(2), 166–173 (2015).
  Medline CASGoogle Scholar
• 24 Holman RR, Bethel MA, Chan JC et al. Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. Am. Heart J. 168(1), 23–29 (2014).
  Medline CASGoogle Scholar
• 25 Yip WCY, Sequeira IR, Plank LD, Poppitt SD. Prevalence of Pre-Diabetes across Ethnicities: a review of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) for classification of dysglycaemia. Nutrients 9(1273), 1–18 (2017).
  Google Scholar
• 26 Sniderman AD, Bhopal R, Prabhakaran D, Sarrafzadegan N, Tchernof A. Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis. Int. J. Epidemiol. 36(1), 220–225 (2007).
  MedlineGoogle Scholar
• 27 O'Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am. J. Cardiol. 100(5), 899–904 (2007).
  MedlineGoogle Scholar
• 28 Kitada S, Otsuka Y, Kokubu N et al. Post-load hyperglycemia as an important predictor of long-term adverse cardiac events after acute myocardial infarction: a scientific study. Cardiovasc. Diabetol. 9, 75 (2010).
  MedlineGoogle Scholar
• 29 Wang JS, Tu ST, Lee IT et al. Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring. Diabetes Metab. Res. Rev. 27(1), 79–84 (2011).
  Medline CASGoogle Scholar
• 30 Weng J, Soegondo S, Schnell O et al. Efficacy of acarbose in different geographical regions of the world: analysis of a real-life database. Diabetes Metab. Res. Rev. 31(2), 155–167 (2015).
  Medline CASGoogle Scholar
• 31 van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 28(1), 154–163 (2005).
  Medline CASGoogle Scholar
• 32 Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: collaborative analysis of diagnostic criteria in europe. Lancet 354(9179), 617–662 (1999).
  MedlineGoogle Scholar
• 33 Sarwar N, Gao P, Seshasai SR et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375(9733), 2215–2222 (2010).
  Medline CASGoogle Scholar
• 34 Ando T, Okada S, Niijima Y et al. Impaired glucose tolerance, but not impaired fasting glucose, is a risk factor for early-stage atherosclerosis. Diabet. Med. 27(12), 1430–1435 (2010).
  Medline CASGoogle Scholar
• 35 Tominaga M, Eguchi H, Manaka H et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The funagata diabetes study. Diabetes Care 22(6), 920–924 (1999).
  Medline CASGoogle Scholar
• 36 Mah E, Noh SK, Ballard KD, Matos ME, Volek JS, Bruno RS. Postprandial hyperglycemia impairs vascular endothelial function in healthy men by inducing lipid peroxidation and increasing asymmetric dimethylarginine:arginine. J. Nutr. 141(11), 1961–1968 (2011).
  Medline CASGoogle Scholar
• 37 Mah E, Bruno RS. Postprandial hyperglycemia on vascular endothelial function: mechanisms and consequences. Nutr. Res. 32(10), 727–740 (2012).
  Medline CASGoogle Scholar
• 38 Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in Type 2 diabetes mellitus. Circulation 110(2), 214–219 (2004).
  Medline CASGoogle Scholar
• 39 Gimbrone MA Jr, Garcia-Cardena G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ. Res. 118(4), 620–636 (2016).
  Medline CASGoogle Scholar
• 40 van den Oord SC, Sijbrands EJ, ten Kate GL et al. Carotid intima-media thickness for cardiovascular risk assessment: systematic review and meta-analysis. Atherosclerosis 228(1), 1–11 (2013).
  Medline CASGoogle Scholar
• 41 Hanefeld M, Chiasson JL, Koehler C et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 35(5), 1073–1078 (2004).
  Medline CASGoogle Scholar
• 42 Rudofsky G Jr, Reismann P, Schiekofer S et al. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs. Horm. Metab. Res. 36(9), 630–638 (2004).
  Medline CASGoogle Scholar
• 43 Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. Circ. Res. 108(9), 1122–1132 (2011).
  Medline CASGoogle Scholar
• 44 Chang CH, Chang YC, Lin JW, Chen ST, Chuang LM, Lai MS. Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study. J. Clin. Endocrinol. Metab. 100(3), 1121–1129 (2015).
  Medline CASGoogle Scholar
• 45 Holman RR, Haffner SM, McMurray JJ et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N. Engl. J. Med. 362(16), 1463–1476 (2010).
  Medline CASGoogle Scholar
• 46 Nathan DM. Diabetes: advances in diagnosis and treatment. JAMA 314(10), 1052–1062 (2015).
  Medline CASGoogle Scholar
• 47 Task Force M, Ryden L, Grant PJ et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur. Heart J. 34(39), 3035–3087 (2013).
  MedlineGoogle Scholar
• 48 Li G, Zhang P, Wang J et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 371(9626), 1783–1789 (2008).
  MedlineGoogle Scholar
• 49 Chan JC, Zhang Y, Ning G. Diabetes in China: a societal solution for a personal challenge. Lancet Diabetes Endocrinol. 2(12), 969–979 (2014).
  MedlineGoogle Scholar
• 50 Asakura M, Kim J, Asanuma H et al. Does treatment of impaired glucose tolerance improve cardiovascular outcomes in patients with previous myocardial infarction? Cardiovasc. Drugs Ther. 31(4), 401–411 (2017).
  Medline CASGoogle Scholar
• 51 Oe H, Nakamura K, Kihara H et al. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with Type 2 diabetes: results of the 3D trial. Cardiovasc. Diabetol. 14, 83 (2015).
  MedlineGoogle Scholar
• 52 Shimabukuro M, Tanaka A, Sata M et al. Alpha-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study. Cardiovasc. Diabetol. 16(1), 86 (2017).
  MedlineGoogle Scholar
• 53 Kitano D, Chiku M, Li Y et al. Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia. Cardiovasc. Diabetol. 12(92), 1186–1475 (2013).
  Google Scholar